Organon & Co (OGN) delivered better-than-expected financial results for the third quarter of fiscal 2025. The company reported earnings per share (EPS) of $1.01, surpassing Wall Street's consensus estimate of $0.95 by $0.06. Revenue matched expectations, coming in at $1.6 billion.
The firm will host an earnings conference call to discuss these results and offer further insights into its business performance. With a market capitalization of $1.8 billion and a price-to-earnings (P/E) ratio of 2.52, Organon operates within the pharmaceuticals industry, focusing on women's health, biosimilars, and established brands. The company is headquartered in Jersey City, New Jersey, and employs 10,000 full-time staff.
This earnings report provides insight into Organon & Co's operational performance and financial health. Exceeding analyst expectations may indicate stronger-than-anticipated business fundamentals. Investors are encouraged to review the full earnings release and listen to management commentary for complete context on the quarter's performance and future outlook. Upcoming earnings are scheduled for August 2, 2026, with EPS estimated at $1.04 and revenue expected to remain steady at $1.6 billion.